These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18206084)

  • 1. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
    Guhl G; Díaz-Ley B; Fernández-Herrera J
    Actas Dermosifiliogr; 2008; 99(1):5-33. PubMed ID: 18206084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of biologic agents in medicine and dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2005 Mar; 24(1):2-9. PubMed ID: 15900793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies in dermatologic disorders.
    Fallen RS; Terpstra CR; Lima HC
    Med Clin North Am; 2012 May; 96(3):565-82, x-xi. PubMed ID: 22703856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic agents in the treatment of psoriasis.
    Guarneri F; Guarneri C; Guarneri B
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
    Bremmer M; Deng A; Gaspari AA
    Dermatitis; 2009; 20(5):243-56. PubMed ID: 19807998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R; Tutrone WD; Weinberg JM
    Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH; Prinz J; Gottlieb AB
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications and adverse reactions in the use of newer biologic agents.
    Callen JP
    Semin Cutan Med Surg; 2007 Mar; 26(1):6-14. PubMed ID: 17349557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic monoclonal antibodies in ophthalmology.
    Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
    Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies in dermatological practice].
    Rudnicka L; Szymańska E; Oledzka E; Olszewska M
    Pol Merkur Lekarski; 2005 Dec; 19(114):839-42. PubMed ID: 16521437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label uses of biologic agents in dermatology: a 2006 update.
    Kerns MJ; Graves JE; Smith DI; Heffernan MP
    Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining traditional agents and biologics for the treatment of psoriasis.
    Cather JC; Menter A
    Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD; Saini R; Weinberg JM
    IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.